This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Signify Health Valuation

Is SGFY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SGFY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SGFY ($30.49) is trading above our estimate of fair value ($18.23)

Significantly Below Fair Value: SGFY is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SGFY?

Key metric: As SGFY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SGFY. This is calculated by dividing SGFY's market cap by their current earnings.
What is SGFY's PE Ratio?
PE Ratio71.4x
EarningsUS$76.50m
Market CapUS$7.21b

Price to Earnings Ratio vs Peers

How does SGFY's PE Ratio compare to its peers?

The above table shows the PE ratio for SGFY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.3x
OPCH Option Care Health
18.4x4.4%US$3.9b
CHE Chemed
25.8x8.8%US$7.7b
DVA DaVita
14.6x4.3%US$12.0b
CRVL CorVel
70.2xn/aUS$5.8b
SGFY Signify Health
71.4x11.8%US$7.2b

Price-To-Earnings vs Peers: SGFY is expensive based on its Price-To-Earnings Ratio (71.4x) compared to the peer average (26x).


Price to Earnings Ratio vs Industry

How does SGFY's PE Ratio compare vs other companies in the US Healthcare Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
THC Tenet Healthcare
3.8x-39.2%US$12.12b
NEUE NeueHealth
1.2xn/aUS$33.51m
IDXG Interpace Biosciences
2.4xn/aUS$10.60m
FZMD Fuse Medical
2.2xn/aUS$8.67m
SGFY 71.4xIndustry Avg. 21.1xNo. of Companies10PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SGFY is expensive based on its Price-To-Earnings Ratio (71.4x) compared to the US Healthcare industry average (21.8x)


Price to Earnings Ratio vs Fair Ratio

What is SGFY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SGFY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio71.4x
Fair PE Ratio29.3x

Price-To-Earnings vs Fair Ratio: SGFY is expensive based on its Price-To-Earnings Ratio (71.4x) compared to the estimated Fair Price-To-Earnings Ratio (29.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SGFY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Dec ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Nov ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Oct ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Sep ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Aug ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Jul ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Jun ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
May ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Apr ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Mar ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Feb ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Jan ’25n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Dec ’24n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Nov ’24n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Oct ’24n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Sep ’24n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Aug ’24n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Jul ’24n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Jun ’24n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
May ’24n/a
US$28.88
0%
9.7%US$30.50US$24.00n/a4
Apr ’24US$30.49
US$28.88
-5.3%
9.7%US$30.50US$24.00n/a4
Mar ’24US$28.75
US$29.42
+2.3%
8.2%US$30.50US$24.00n/a6
Feb ’24US$28.58
US$29.07
+1.7%
8.2%US$30.50US$24.00n/a7
Jan ’24US$28.66
US$29.07
+1.4%
8.2%US$30.50US$24.00n/a7
Dec ’23US$28.64
US$29.07
+1.5%
8.2%US$30.50US$24.00n/a7

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/30 09:17
End of Day Share Price 2023/03/28 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Signify Health, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vikram KesavabhotlaBaird
Steven ValiquetteBarclays
Sarah JamesBarclays